New drug duo shows promise for rare blood cancer
Disease control
Completed
This completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. …
Phase: PHASE2 • Sponsor: Won Seog Kim • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC